The lawyers at Saiontz & Kirk are no longer investigating Ketek Liver Damage Lawsuits. The information on this page is provided for information purposes only.
The manufacturer of Ketek failed to properly warn of the increased risk of liver failure or death as a side effect of the antibiotic. The antibiotic, Ketek has been linked to serious and potentially fatal injuries which the manufacturer failed to adequately warn about.
The lawyers at Saiontz & Kirk, P.A. previously reviewed potential Ketek lawsuits for individuals who used the antibiotic and have suffered:
- Liver Damage
- Liver Failure
- Acute Respiratory Failure
- Aggravation of Myasthenia Gravis
KETEK CLASS ACTION SUITS
Ketek (telithromycin) is manufactured and sold by Sanofi-Adventis. It is a new antibiotic which was approved in 2004 for treatment of respiratory tract infections, sinusitis, pneumonia and bronchitis. There have been recent findings of fraud during the clinical trials used to gain FDA approval. Given the safety concerns, many experts have questioned whether the medication should have ever been sold.
The manufacturer was aware of the increased risk of liver damage associated with ketek at the time they introduced the medication. However, it was not until reports of liver failure and death began to surface that they added a Keteck liver damage warning. A recent FDA committee has recommended that the manufacturer not be allowed to market the antibiotic for sinusitis or bronchitis and that a stronger “black box” warning be required by the FDA.
>>NEWS 2/14/2007: Ketek liver damage risks lead to restrictions on use
Ketek class action suits and individual claims are being investigated since the risks associated with the medication clearly outweigh the minimal benefits provided to users. Many experts have indicated that the antibiotic Ketek should not have ever been approved for sale by the FDA.
New cases are no longer being accepted by Saiontz & Kirk, P.A. This page is maintained for informational purposes only.